Evolving treatment approaches for early breast cancer

Breast Cancer Research and Treatment

Volumn 89, Issue SUPPL., 2005, Pages

  Campos, Susana M ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Adjuvant therapy; Breast cancer; Chemotherapy; Endocrine therapy; Epoetin alfa; Hormone therapy; Supportive care

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; EXEMESTANE; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; LETROZOLE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PACLITAXEL; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN; TAXANE DERIVATIVE;

ADJUVANT CHEMOTHERAPY; ANEMIA; ARTHRALGIA; ARTHRITIS; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; DEATH; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENDOMETRIUM CANCER; FATIGUE; FEBRILE NEUTROPENIA; FRACTURE; HORMONAL THERAPY; HOT FLUSH; HUMAN; LEUKOCYTE COUNT; LEUKOCYTE DISORDER; METASTASIS; MULTIMODALITY CANCER THERAPY; MUSCULOSKELETAL DISEASE; MYALGIA; OSTEOPOROSIS; PARTIAL MASTECTOMY; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; SIDE EFFECT; SLEEP DISORDER;

ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; NEOPLASM STAGING;

EID: 17044394034     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-005-0142-0     Document Type: Review

References (36)

1. Early Breast Cancer Trialists' Collaborative Group 1998 Polychemotherapy for early breast cancer: an overview of the randomised trials Lancet 352 930 942
2. Early Breast Cancer Trialists' Collaborative Group 1998 Tamoxifen for early breast cancer: an overview of the randomised trials Lancet 351 1451 1467
3. A Goldhirsch WC Wood RD Gelber AS Coates B Thürlimann HJ Senn 2003 Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer J Clin Oncol 21 3357 3365
4. RW Blamey 2002 Guidelines on endocrine therapy of breast cancer EUSOMA Eur J Cancer 38 615 634
5. National Comprehensive Cancer Network: Clinical practice guidelines in oncology: Breast cancer. Version 3: 2003
6. BF Cole RD Gelber S Gelber AS Coates A Goldhirsch 2001 Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis Lancet 358 277 286
7. IC Henderson DA Berry GD Demetri CT Cirrincione LJ Goldstein S Martino JN Ingle MR Cooper DF Hayes KH Tkaczuk G Fleming JF Holland DB Duggan JT Carpenter E Frei III RL Schilsky WC Wood HB Muss L Norton 2003 Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer J Clin Oncol 21 976 983
8. EP Mamounas J Bryant BC Lembersky B Fisher JN Atkins L Fehrenbacher PC Raich G Yothers A Soran N Wolmark 2003 Paclitaxel (T) following doxorubicin/cyclophosphamide (AC) as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. Proc Am Soc Clin Oncol 22 4 (abstract 12)
9. Mamounas EP, Bryant J, Lembersky BC, Fisher B, Atkins JN, Fehrenbacher L, Raich PC, Yothers G, Soran A, Wolmark N: Paclitaxel (T) following doxorubicin/cyclophosphamide (AC) as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. Presentation at the 39th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, USA, May 31-June 3, 2003
10. JM Nabholtz T Pienkowski J Mackey M Pawlicki JP Guastalla C Vogel C Weaver B Walley M Martin L Chap E Tomiak E Juhos R Guevin A Howell J Hainsworth T Fornander S Blitz S Gazel C Loret A Riva 2002 Phase III trial comparing TAC (docetaxel, doxorubicin cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: interim analysis of the BCIRG 001 study. Proc Am Soc Clin Oncol 21 36a abstract 141
11. Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, Tomiak E, Al-Tweigeri T, Chap L, Juhos E, Guevin R, Howell A, Fornander T, Hainsworth J, Coleman R, Vinholes J, Modiano M, Pinter T, Hugh J, Nabholtz JM, Loret C, Rupin M, Blitz S, Riva A, Vogel C, On behalf of the BCIRG 001 Investigators: TAC improves disease free survival and overall survival over FAC in node positive early breast cancer patients, BCIRG 001: 55 months follow-up. In: 26th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, USA, December 3-6, 2003 (abstract 43)
12. K Boér I Láng E Juhos T Pintér J Szántó 2003 Hungarian experience with docetaxel combination (TAC) in the adjuvant treatment of breast cancer. Results of BCIRG 001 randomized, multicentric, phase III trial Magy Onkol 47 141 148
13. ML Citron DA Berry C Cirrincione C Hudis EP Winer WJ Gradishar NE Davidson S Martino R Livingston JN Ingle EA Perez J Carpenter D Hurd JF Holland BL Smith CI Sartor EH Leung J Abrams RL Schilsky HB Muss L Norton 2003 Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741 J Clin Oncol 21 1431 1439
14. Moebus V, Kurbacher C, Nitz U, Untch M, Eidtmann H, duBois A, Kuhn W, Lueck H-J, Thomssen C, Jackisch C: Epoetin alpha prevents anemia and transfusions in patients (pts) receiving dose-dense sequential chemotherapy (ETC). In: 26th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, USA, December 3-6, 2003 (abstract 638)
15. JC Egrie JK Browne 2001 Development and characterization of novel erythropoiesis stimulating protein (NESP) Nephrol Dial Transplant 16 Suppl 3 3 13
16. IC Macdougall 2002 Optimizing the use of erythropoietic agents - pharmacokinetic and pharmacodynamic considerations Nephrol Dial Transplant 17 Suppl 5 66 70
17. U Denison J Baumann C Peters-Engl H Samonigg P Krippl A Lang A Obermair H Wagner P Sevelda 2003 Incidence of anaemia in breast cancer patients receiving adjuvant chemotherapy Breast Cancer Res Treat 79 347 353
18. J Kirshner M Hatch DD Hennessy M Fridman RE Tannous 2004 Anemia in stage II and III breast cancer patients treated with adjuvant doxorubicin and cyclophosphamide chemotherapy Oncologist 9 25 32
19. GD Lawless JM Ford 2004 Cumulative prevalence of anemia in early-stage breast cancer (ESBC) patients Blood 96 390b (abstract 5447)
20. JA O' Shaughnessy 2002 Effects of epoetin alfa on cognitive function, mood, asthenia, and quality of life in women with breast cancer undergoing adjuvant chemotherapy Clin Breast Cancer 3 Suppl 3 S116 S120
21. D Greene LM Nail VK Fieler D Dudgeon LS Jones 1994 A comparison of patient-reported side effects among three chemotherapy regimens for breast cancer Cancer Pract 2 57 62
22. JA Broeckel PB Jacobsen J Horton L Balducci GH Lyman 1998 Characteristics and correlates of fatigue after adjuvant chemotherapy for breast cancer J Clin Oncol 16 1689 1696
23. TA Ahles AJ Saykin CT Furstenberg B Cole LA Mott K Skalla MB Whedon S Bivens T Mitchell ER Greenberg PM Silberfarb 2002 Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma J Clin Oncol 20 485 493
24. FS van Dam SB Schagen MJ Muller W Boogerd E Wall ME Droogleever Fortuyn S Rodenhuis 1998 Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy J Natl Cancer Inst 90 210 218
25. SB Schagen MJ Muller W Boogerd RM Rosenbrand D van Rhijn S Rodenhuis FS van Dam 2002 Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients Ann Oncol 13 1387 1397
26. Jacobsen PB, Thors CL, Cawley M, Ax E, Grendys ECJ: Relation of decline in hemoglobin to cognitive functioning and fatigue during chemotherapy treatment. In: 38th Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, USA, May 18-21, 2002 (abstract 1542)
27. N Tchen HG Juffs FP Downie QL Yi H Hu I Chemerynsky M Clemons M Crump PE Goss D Warr ME Tweedale IF Tannock 2003 Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer J Clin Oncol 21 4175 4183
28. O'Shaughnessy J, Vukelja S, Savin M, Holmes FA, Jones M, Royall D, George M, von Hoff D: Impact of epoetin alfa on cognitive function, asthenia, and quality of life in women with breast cancer receiving adjuvant or neoadjuvant chemotherapy: analysis of 6-month follow-up data. In: 25th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, USA, December 11-14, 2002 (poster 530)
29. Hudis CA, Williams D, Gralow JR, and the Procrit® Study Group: Epoetin alfa maintains hemoglobin levels and quality of life in breast cancer patients during conventional adjuvant chemotherapy. In: 25th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, USA, December 11-14, 2002 (poster 539)
30. Hudis CA, Williams D: Early treatment of mild anemia with once-weekly epoetin alfa significantly improves hemoglobin and quality of life in early-stage breast cancer patients during conventional adjuvant chemotherapy. In: 26th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, USA, December 3-6, 2003 (poster 639)
31. The ATAC (Arimidex Tamoxifen Alone or in Combination) Trialists' Group 2002 Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial Lancet 359 2131 2139
32. The ATAC (Arimidex Tamoxifen Alone or in Combination) Trialists' Group 2003 Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses Cancer 98 1802 1810
33. PE Goss JN Ingle S Martino NJ Robert HB Muss MJ Piccart M Castiglione D Tu LE Shepherd KI Pritchard RB Livingston NE Davidson L Norton EA Perez JS Abrams P Therasse MJ Palmer JL Pater 2003 A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer N Engl J Med 349 1793 1802
34. Boccardo F, Rubagotti A, Amoroso D, Mesiti M, Massobrio M, Benedetto C, Porpiglia M, Rinaldini M, Paladini G, Distante V, Franchi R, Failla G, Bordonaro R, Sismondi P: Anastrozole appears to be superior to tamoxifen in women already receiving adjuvant tamoxifen treatment. In: 26th Annual San Antonio Breast Cancer Symposium December 3-6, 2003 (abstract 3)
35. RC Coombes E Hall LJ Gibson R Paridaens J Jassem T Delozier SE Jones I Alvarez G Bertelli O Ortmann AS Coates E Bajetta D Dodwell RE Coleman LJ Fallowfield E Mickiewicz J Andersen PE Lonning G Cocconi A Stewart N Stuart CF Snowdon M Carpentieri G Massimini JM Bliss 2004 A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer N Engl J Med 350 1081 1092
36. V Shilling V Jenkins L Fallowfield T Howell 2003 The effects of hormone therapy on cognition in breast cancer J Steroid Biochem Mol Biol 86 405 412